Sergio Vegas-Suarez
Overview
Explore the profile of Sergio Vegas-Suarez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vegas-Suarez S, Morera-Herreras T, Requejo C, Lafuente J, Moratalla R, Miguelez C, et al.
Front Pharmacol
. 2022 Sep;
13:953652.
PMID: 36133803
Cortical information is transferred to the (SNr) and the entopeduncular nucleus (EP), the output structures of the basal ganglia (BG), through three different pathways: the hyperdirect trans-subthalamic and the direct...
2.
Vegas-Suarez S, Simon J, Martinez-Chantar M, Moratalla R
Front Physiol
. 2022 May;
13:864263.
PMID: 35634148
Chronic liver diseases include a broad group of hepatic disorders from different etiologies and with varying degrees of progression and severity. Among them, non-alcoholic fatty (NAFLD) and alcoholic (ALD) liver...
3.
Vegas-Suarez S, Aristieta A, Requejo C, Bengoetxea H, Lafuente J, Miguelez C, et al.
Br J Pharmacol
. 2021 Mar;
178(12):2516-2532.
PMID: 33686657
Background And Purpose: l-DOPA prolonged treatment leads to disabling motor complications as dyskinesia that could be decreased by drugs acting on 5-HT receptors. Since the internal segment of the globus...
4.
Vegas-Suarez S, Pisano C, Requejo C, Bengoetxea H, Lafuente J, Morari M, et al.
Br J Pharmacol
. 2020 May;
177(17):3957-3974.
PMID: 32464686
Background And Purpose: l-DOPA-induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5-HT partial agonist) have shown promising results in the treatment of...
5.
Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T, De Deurwaerdere P, Miguelez C
Front Pharmacol
. 2020 Apr;
11:435.
PMID: 32322208
Nowadays it is well accepted that in Parkinson's disease (PD), the neurodegenerative process occurs in stages and that damage to other areas precedes the neuronal loss in the substantia nigra...
6.
Vegas-Suarez S, Paredes-Rodriguez E, Aristieta A, Lafuente J, Miguelez C, Ugedo L
Int Rev Neurobiol
. 2019 Jul;
146:259-279.
PMID: 31349930
Parkinson's disease (PD) is characterized by the degeneration of dopaminergic neurons in the substantia nigra, the depletion of striatal dopamine and the presence of Lewy aggregates containing alpha-synuclein. Clinically, there...